Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study - Takeaways - MDSpire

Real-world effectiveness and safety of dupilumab therapy in children ≤6 years with uncontrolled persistent asthma: a propensity-matched retrospective cohort study

  • By

  • Ahlam Mazi

  • Azizah Aljohany

  • Michele Fouad

  • Hanaa Hamadallah

  • Esraa M. Bukhari

  • Doaa Bayomi

  • Samahir Alsulaimani

  • Nour Gazzaz

  • Muhannad Sharara

  • Monica Dobs

  • June 15, 2026

  • 0 min

Share

  • 1

    Dupilumab is a biological agent effective in older children with uncontrolled asthma but lacks data for children aged six years and younger.

  • 2

    A retrospective cohort analysis compared outcomes in children ≤6 years on dupilumab plus standard treatment versus standard treatment alone.

  • 3

    Dupilumab therapy was associated with reduced acute exacerbations, oral corticosteroid use, and emergency room visits at 6 and 12 months.

  • 4

    The risk of anaphylaxis was higher in children receiving dupilumab compared to those on standard treatment alone.

  • 5

    This study provides real-world evidence on the efficacy and safety of dupilumab for managing uncontrolled asthma in young children.

Original Source(s)

Related Content